Files

519004.pdf (87.05 KB)

Document type

Article

Version

Published version

Publication date

2002-11-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/172746

Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas

Journal Title

Authors

Director/Tutor

Additional contribution

Journal ISSN

Volume Title

Abstract

We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients.

Related resource

Subject

Anticossos monoclonals, Ús terapèutic, Limfomes

Subject (English)

Monoclonal antibodies, Therapeutic use, Lymphomas

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)

Citation

DOMINGO DOMÈNECH, Eva, et al. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica. 2002. Vol. 87, num. 11, pags. 1229-1230. ISSN 0390-6078. [consulted: 16 of October of 2026]. Available at: https://hdl.handle.net/2445/172746

Export metadata

JSON - METS

Share record